Anti-infective Agents : Penicillins
IPIPE1 “Piperacillin/Tazobactam for injection”
Each vial contains piperacillin sodium 2 gm, tazobactam sodium 0.25 gm, 2.25gm/vial
IPISU2 “Pisutam powder for IV injection”
Each vial contains piperacillin sodium 2 gm, tazobactam sodium 0.25 gm, 2.25gm/vial
IPISU9 “Pisutam powder for IV injection”
Each vial contains piperacillin sodium 4 gm, tazobactam sodium 0.5 gm, 4.5gm/vial
ITAZO1 “Tazocin-Lyo injection”
Each vial contains piperacillin sodium2 gm, tazobactam sodium 0.25 gm, 2.25gm/vial
適應症：對piperacillin具有感受性以及對piperacillin具抗藥性，但對piperacillin tazobactam有感受性之β-lactamase產生菌株所引起之中至嚴重程度感染。
Usual dose:
Susceptible infections (moderate to severe): IV, 3.375 gm q6h.
Nosocomial pneumonia: IV, 3.375 gm q4h with an aminoglycoside.
Dose adjustment:
Renal failure: CrCl 20-40 ml/min, 2.25 mg q6h;< 20 ml/min 2.25 mg q8h
Hemodialysis: max. 2.25 gm q8h; (0.75 g after each dialysis session).
Adverse effect:
Common: injection site reaction, pruritus, rash, diarrhea, nausea, vomiting, allergic reaction, headache.
Serious: anaphylaxis.